课题基金 / 基金详情

Developmental study on anti-dementia drugs by using neuropeptides related to memory disturbance

Developmental study on anti-dementia drugs by using neuropeptides related to memory disturbance
记忆障碍相关神经肽抗痴呆药物的开发研究
批准号:
11672197
负责人:
UKAI Makoto
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2001

项目摘要

项目成果

UKAI Makoto的其他基金

相似基金

相关文献

中文摘要
翻译
研究了μ-阿片受体激动剂内吗啡肽-1和-2对短期和长期记忆的影响。此外,本研究旨在寻找新的治疗痴呆症的药物。μ-阿片受体拮抗剂β-funalcumamine可显著拮抗内吗啡肽引起的短、长时记忆障碍。μ1阿片受体拮抗剂纳洛嗪对内吗啡肽-1引起的短期记忆障碍有明显改善作用,但对内吗啡肽-2引起的短期记忆障碍无明显改善作用。纳洛嗪、胆碱酯酶抑制剂或毒扁豆碱可改善长时记忆障碍。多巴胺D2受体激动剂RU 24213对内吗啡肽引起的短、长时记忆障碍无明显影响,多巴胺D2受体拮抗剂(-)-舒必利可显著对抗内吗啡肽引起的短、长时记忆障碍。上述结果表明,μ1-阿片受体、多巴胺D2受体和胆碱能神经传递在内吗啡肽引起的记忆障碍中起主要作用。此外,μ1-阿片受体拮抗剂可能用作新型抗痴呆药物。
英文摘要
The effects of the μ-opioid receptor agonists endomorphin-1 and -2 on short- and long-term memory were examined. In addition, the present study was designed to find novel therapeutic drugs for dementia. The μ-opioid receptor antagonist β-funaltrexamine significantly antagonized the endomorphins-induced disturbance of short- and long-term memory. Although the disturbance of short-term memory with endomorphm-1 was significantly improved by the μ1-opioid receptor antagonist naloxonazine, such drug was without any significant effects on the endomorphin-2-induced disturbance of short-term memory. Naloxonazine and the cholmesterase inhibit or physostigmine ameliorated the disturbance of long-term memory. The dopamine D2 receptor agonist RU24213 did not significantly influence the disturbance of short- and long-term memory induced by endomorpnms, the dopamine D2 receptor antagonist (-)-sulpiride significantly antagonized the endomorphins-induced disturbance of short- and long-term memory. From the above results, μ1-opioid receptor, dopamine D2 receptor and cholinergic neurotransmission play a major role in the memory disturbance with endomorpnins. Furthermore, it is possible that μ1-opioid receptor antagonists are useful as novel anti-dementia drugs.
期刊论文(32)
专著(0)
科研奖励(0)
会议论文
Makoto Ukai, Yoshiko Watanabe and Tsutomu Kameyama: "Effects of endomorphins-1 and 2, endogenous μ-opioid recept or agonists, on spontaneous alternation performance in mice"Eur. J. Pharmacol.. 395. 211-215 (2000)
Makoto Ukai、Yoshiko Watanabe 和 Tsutomu Kameyama:“内吗啡肽 1 和 2、内源性 μ-阿片受体或激动剂对小鼠自发交替行为的影响”Eur. J. Pharmacol.. 395. 211-215 (2000)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takayoshi Mamiya: "Morphine tolerance and dependence in the nociceptin receptor knockout mice"J.Neural Transm.. 108. 1349-1361 (2001)
Takayoshi Mamiya:“伤害感受肽受体敲除小鼠的吗啡耐受性和依赖性”J.Neural Transm.. 108. 1349-1361 (2001)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
鵜飼 良: "生理活性peptideによる脳機能障害治療薬の開発研究"応用薬理. 57. 138-139 (1999)
Ryo Ukai:“使用生物活性肽治疗脑功能障碍的药物的开发研究”应用药理学 57. 138-139 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
鵜飼 良: "Endomorphinsと学習・記憶"名城大学総合研究所紀要. 4. 175-176 (1999)
Ryo Ukai:“内吗啡肽与学习和记忆” 名城大学研究所通报 4. 175-176 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
26
    Development of novel therapeutic drugs for Alzheimer disease
    • 批准号:
      14572081
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2002
    • 负责人:
      UKAI Makoto
    • 依托单位:
    Establishment of Animal Models of Dementia with Neuropeptides and Development Study of Anti-Dementia Drugs
    • 批准号:
      09672261
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.02万
    • 财政年份:
      1997
    • 负责人:
      UKAI Makoto
    • 依托单位:
    Development study of preventive and therapeutic drugs for Alzheimertype senile dementia by using biologically active peptides
    • 批准号:
      07672396
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.09万
    • 财政年份:
      1995
    • 负责人:
      UKAI Makoto
    • 依托单位:
    海外基金